In:
Thoracic Cancer, Wiley, Vol. 13, No. 23 ( 2022-12), p. 3420-3430
Abstract:
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in‐depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.
Type of Medium:
Online Resource
ISSN:
1759-7706
,
1759-7714
DOI:
10.1111/1759-7714.14693
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2559245-2
